Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05900401 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Delayed Tolerance Through Mixed Chimerism

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years 11 months later Dec 2028 → Dec 2031
See other at-risk trials from Massachusetts General Hospital

Record History

  1. Primary completion pushed from Dec 2028 to Dec 2031 Enrollment reopened · Completion pushed from Dec 2030 to Dec 2032 · Eligibility criteria expanded, about 37 words · 1 more Show 4 more changesShow less
    • Enrollment reopened
    • Completion pushed from Dec 2030 to Dec 2032
    • Eligibility criteria expanded, about 37 words
    • Site details revised
  2. Re-verified, no change to tracked fieldsv6
  3. Trial status: Recruiting to Active, Not Recruiting Site details revisedv5 Show 1 more changeShow less
    • Site details revised
  4. Eligibility criteria shortened, about 16 words Site contact updatedv4 Show 1 more changeShow less
    • Site contact updated

    See this version in full on ClinicalTrials.gov ↗

  5. Primary completion date: Dec 2026 to Dec 2028 Completion date: Dec 2029 to Dec 2030v3 Show 1 more changeShow less
    • Completion date: Dec 2029 to Dec 2030
  6. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jun 2023 to Oct 1, 2023 · Study sites: 0 to 1 · Interventions: Bone Marrow Transplant (Other), Combination of Fludarabine, Cyclophosphamide, Rituximab & Siplizumab (Drug), Peripheral Blood Stem Cell… to Bone Marrow Transplant (Other), Cyclophosphamide (Drug), Fludarabine (Drug), Peripheral Blood Stem Cell Collection (Procedure), Rituximab… · 1 morev2 Show 4 more changesShow less
    • Start date changed from estimate of Jun 2023 to Oct 1, 2023
    • Study sites: 0 to 1
    • Interventions: Bone Marrow Transplant (Other), Combination of Fludarabine, Cyclophosphamide, Rituximab & Siplizumab (Drug), Peripheral Blood Stem Cell… to Bone Marrow Transplant (Other), Cyclophosphamide (Drug), Fludarabine (Drug), Peripheral Blood Stem Cell Collection (Procedure), Rituximab…
    • Study description expanded, about 9 words

    See this version in full on ClinicalTrials.gov ↗

  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will examine the safety and effectiveness of a bone marrow transplant after kidney transplant (from either a living or deceased donor). An investigational medication and other treatments will be given prior to and after the transplant to help protect the transplanted kidney from being attacked by the body's immune system
Trial Details
NCT Number NCT05900401
Lead Sponsor Massachusetts General Hospital
Collaborators: Ossium Health, Inc., ITB-Med LLC
Conditions Kidney Failure, Kidney Transplant; Complications, Chimera
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov